New Korus Technology Set

New Korus Technology Set to Transform Industry Standards Invetech has launched Korus™, a closed system for autologous cell therapies with wash and cell-wash capabilities using gentle reverse-flow centrifugation. Korus has the potential to transform cell therapy industry standards, with supporting data demonstrating improved manufacturing performance compared to samples prepared with standard washing. The system delivers purified cell populations for downstream processing improvement and commercial manufacturing, resulting in better overall process performance through higher recovery and purity of target cells. [caption id="attachment_141634" align="aligncenter"] Korus Reverse-Flow Centrifuge System from Invetech[/caption] Innovation in cell processing is critically needed to improve processes, enhance GMP manufacturing performance, and provide yields high enough for viable therapy. Developers can now accelerate clinical development with Invetech's new Korus system, scale efficiently, and be ready to reach market first. Invetech President Andreas Knaack states, "Our industry needs efficient and scalable manufacturing technologies that can deliver high-quality treatments cost-effectively to accelerate the commercialization of cell and gene therapies." "The new technology offering demonstrated by our Korus™ system represents our commitment to helping make life-saving treatments accessible to more patients." Invetech's Korus system uses a gentle elution process to provide a cleaner cell population for cell therapy manufacturing. The results demonstrate a transformative change in processing starting materials compared with current industry standards, preparing manufacturers for future success. Compared with standard wash protocols, Korus can deliverⁱ: - 31% purer lymphocyte population - 49% improvement in T cell recovery after selection - 70% more T cells during expansion - 2.5-fold improvement in manufacturing yield Integrating Korus technology into a cell therapy manufacturing process can lead to improved downstream performance, including significantly higher target cell recovery during selection and significantly higher cell growth during expansion. The 2.5-fold improvement in manufacturing yield means cell therapy developers can expect to more consistently grow sufficient cells for an appropriate final cell therapy product. During testing in the above internal study, similar lymphocyte recovery performance was observed in both the Korus and CS5+ (wash) control arms despite the increase in purity in the Korus arm due to washing. The relative Korus T cell selection recovery and fold expansion were significantly higher, resulting in over 70% more cells being cultured in the Korus arm. Jon Ellis, leading Invetech's Cell Therapy Science and Application team, explains the results of the Korus testing program. "Cell therapy manufacturing productivity must be improved and renewed for the cell therapy industry to achieve its commercialization goals. Our data show that while achieving similar apheresis lymphocyte cell recovery to the control wash process, Korus separated lymphocytes at high purity, which resulted in improvements in downstream performance including greater Dynabead cell selection recovery and fold expansion. Overall, this innovation in cell processing will reduce the impact of starting material variability, contribute to higher manufacturing yields and lower batch failure risk, and potentially reduce material costs for future therapies." ⁱThe Korus system is for research, laboratory, or advanced manufacturing use only. It is not designed as a medical device for therapeutic or diagnostic procedures. Customers are responsible for approval of Korus use in their own processes or therapies.   SOURCE